{
  "docId": "019de072-f015-70b3-a108-700a038da3d5",
  "docSlug": "ab0daada6947ab44927f267f74789e9c",
  "documentTitle": "Bionomics | Investor Presentation Deck | 16 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 16,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a list-based layout to summarize key company milestones and strategic pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f015-70b3-a108-700a038da3d5/3",
  "deckHref": "/decks/019de072-f015-70b3-a108-700a038da3d5",
  "deckJsonHref": "/decks/019de072-f015-70b3-a108-700a038da3d5.json",
  "deckAnchorHref": "/decks/019de072-f015-70b3-a108-700a038da3d5#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.5,
        "x": 0.13,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "PoC = Proof of Concept; GAD = Generalized Anxiety Disorder; PTSD = Post-Traumatic Stress Disorder; 1. Wise et al 2020, Biological Psychiatry; Perkins et al 2021, Molecular Psychiatry",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f92be8cb-f3ce-4a6a-8e4e-0787312025a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.08,
        "y": 0.22
      },
      "kind": "list",
      "text": "Lead asset: BNC210 - a negative allosteric modulator of the α7 Nicotinic Acetylcholine receptor",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04d387b6-c4f8-4e34-b013-6ee9d0888530",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.85,
        "x": 0.08,
        "y": 0.71
      },
      "kind": "list",
      "text": "Well-capitalized balance sheet and cash runway beyond multiple potential near term value-driving milestones; BNC210 IP coverage extending to late 2030’s",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2086ca5e-1254-4eca-b9d7-87e6df6c5a9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.08,
        "y": 0.13
      },
      "kind": "list",
      "text": "Targeting Social Anxiety Disorder (SAD) and PTSD, and cognitive dysfunction associated with Alzheimer’s disease, schizophrenia and other CNS disorders",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "683b12c4-1b76-437a-b9b1-88fc00244871",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.85,
        "x": 0.08,
        "y": 0.31
      },
      "kind": "list",
      "text": "BNC210: Clinical PoC in GAD and FDA Fast Track designation for acute Social Anxiety Disorder (SAD); In Phase 2 PREVAIL trial for acute treatment in SAD; In Phase 2b ATTUNE trial with Fast Track designation from FDA for PTSD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b99d09ad-733d-4926-9b09-7cd6302b35f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.85,
        "x": 0.08,
        "y": 0.51
      },
      "kind": "list",
      "text": "Partnerships & Collaborations: Strategic partnership with Merck; MOU with EmpathBio; Pipeline of partnering candidates targeting potassium (Kv) and sodium (Nav) ion channels",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba523c9e-bba0-4516-bedc-c0f481065966",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.32,
        "x": 0.08,
        "y": 0.03
      },
      "kind": "title",
      "text": "Bionomics Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03c5cf3a-3833-460d-b84b-e0f0c2e9f1ce",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "fd8b386d-c6e8-46ae-ac5c-788dc00a9c5f",
      "evidence": "Bionomics Highlights",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}